Scott I Raskin

Dr. Scott I Raskin

Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2016 in Nanoscale
Verified
Journal Article
Closed access
PDF file
SLShanghao Li
Shanghao Li
DADaniel Amat
Daniel Amat
ZPZhili Peng
Zhili Peng
SVSteven Vanni
Steven Vanni
SRScott I Raskin
Scott I Raskin
Roger LeblancRoger Leblanc
Roger Leblanc
Among various cancers, pediatric brain tumors represent the most common cancer type in children and the second most common cause of cancer related deaths. Anticancer drugs and therapies, such as doxorubicin (Dox), have severe side effects on patients during chemotherapy, especially for children as their bodies are still under development. These side effects are believed to be due to the lack of a delivery system with high efficacy and targeting selectivity, resulting in serious damages of normal cells. To improve the efficacy and selectivity, the transferrin (Trans) receptor mediated endocytosis can be utilized for drug delivery system design, as transferrin receptors are expressed on the blood brain barrier (BBB) and often over expressed in brain tumor cells. Carbon dots (C-Dots) have recently emerged as benign nanoparticles in biomedical applications owing to their good water solubility, tunable surface functionalities and excellent biocompatibility. The unique characteristics of C-Dots make them promising candidates for drug delivery development. In this study, carbon dots–transferrin–doxorubicin covalent conjugate (C-Dots–Trans–Dox) was synthesized, characterized by different spectroscopic techniques and investigated for the potential application as a drug delivery system for anticancer drug doxorubicin to treat pediatric brain tumors. Our in vitro results demonstrate greater uptake of the C-Dots–Trans–Dox conjugate compared to Dox alone presumably owing to the high levels of transferrin receptors on these tumor cells. Experiment showed that C-Dots–Trans–Dox at 10 nM was significantly more cytotoxic than Dox alone, reducing viability by 14–45%, across multiple pediatric brain tumor cell lines.

18 August 2021 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
HCHallie Coltin
Hallie Coltin
LSLakshmikirupa Sundaresan
Lakshmikirupa Sundaresan
KSKyle S. Smith
Kyle S. Smith
PSPatryk Skowron
Patryk Skowron
LMLuca Massimi
Luca Massimi
Vijay RamaswamyVijay Ramaswamy
Vijay Ramaswamy

1 October 2021 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
SRScott I Raskin
Scott I Raskin
SPStacey Van Pelt
Stacey Van Pelt
KTKeri Toner
Keri Toner
PBPreethi Bala Balakrishnan
Preethi Bala Balakrishnan
HDHema Dave
Hema Dave
EYEric Yvon
Eric Yvon
The synovial sarcoma X breakpoint 2 (SSX2) belongs to a multigene family of cancer-testis antigens and can be found overexpressed in multiple malignancies. Its restricted expression in immune-privileged normal tissues suggest that SSX2 may be a relevant target antigen for chimeric antigen receptor (CAR) therapy. We have developed a T cell receptor (TCR)-like antibody (Fab/3) that binds SSX2 peptide 41-49 (KASEKIFYV) in the context of HLA-A∗-0201. The sequence of Fab/3 was utilized to engineer a CAR with the CD3 zeta intra-cellular domain along with either a CD28 or 4-1BB costimulatory endodomain. Human T cells from HLA-A2+ donors were transduced to mediate anti-tumor activity against acute myeloid leukemia (AML) tumor cells. Upon challenge with HLA-A2+/SSX2+ AML tumor cells, CAR-expressing T cells released interferon-γ and eliminated the tumor cells in a long-term co-culture assay. Using the HLA-A2+ T2 cell line, we demonstrated a strong specificity of the single-chain variable fragment (scFv) for SSX2 p41-49 and the closely related SSX3 p41-49, with no response against the others SSX-homologous peptides or unrelated homologous peptides. Since SSX3 has not been observed in tumor cells and expression cannot be induced by pharmacological intervention, SSX241-49 represents an attractive target for CAR-based cellular therapy to treat multiple types of cancer.

13 September 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CZClaudia P. Zapata
Claudia P. Zapata
BCBranko Cuglievan
Branko Cuglievan
CZCatalina M. Zapata
Catalina M. Zapata
RORaquel Olavarrieta
Raquel Olavarrieta
SRScott I Raskin
Scott I Raskin
GAGuillermo De Angulo
Guillermo De Angulo

3 December 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
ALAudrey-Anne Lamoureux
Audrey-Anne Lamoureux
MFMichael J. Fisher
Michael J. Fisher
LLLauriane Lemelle
Lauriane Lemelle
EPElke Pfaff
Elke Pfaff
PAPouneh Amir-Yazdani
Pouneh Amir-Yazdani
Sébastien PerreaultSébastien Perreault
Sébastien Perreault
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults (P < 0.0001). Patients with LGG also had a better outcome when compared with HGG (P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.

17 December 2020 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
ECErin E. Crotty
Erin E. Crotty
KDKira M. Downey
Kira M. Downey
LFLauren M. Ferrerosa
Lauren M. Ferrerosa
CFCatherine T. Flores
Catherine T. Flores
BHBindu Hegde
Bindu Hegde
HOHideho Okada
Hideho Okada
Children with high-grade gliomas (pHGGs) represent a clinical population in substantial need of new therapeutic options given the inefficacy and toxicity of current standard-of-care modalities. Alt...